Nifty
:
24363.30
Sensex
:
79857.79
-232.85 (-0.95%)
-765.47 (-0.95%)
Nifty
Sensex
:
:
24363.30
79857.79
-232.85 (-0.95%)
-765.47 (-0.95%)

Zydus Lifesciences Ltd.

Pharmaceuticals & Drugs - Global

Rating :
61/99

BSE: 532321 | NSE: ZYDUSLIFE

NSE BSE
936.15
08-Aug-2025
  • Open
  • High
  • Low
  • Previous Close
  •  949.8
  •  952.05
  •  932.05
  •  944.45
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  589784
  •  555358783
  •  1298
  •  795

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 94,133.19
  • 20.80
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 94,345.89
  • 1.18%
  • 3.93

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 74.99%
  • 0.56%
  • 5.46%
  • FII
  • DII
  • Others
  • 7.13%
  • 10.89%
  • 0.97%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 9.44
  • 10.04
  • 10.48

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 11.46
  • 15.28
  • 14.05

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 8.98
  • 15.71
  • 33.68

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 23.11
  • 24.06
  • 23.44

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 3.80
  • 3.73
  • 3.87

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 15.00
  • 15.14
  • 14.93

Earnings Forecasts:

(Updated: 06-06-2025)
Description
2024
2025
2026
2027
Adj EPS
38.14
44.97
45.35
42.82
P/E Ratio
24.55
20.82
20.64
21.86
Revenue
19022
23242
25229
26280
EBITDA
5303
6895
6841
6507
Net Income
3860
4526
4584
4329
ROA
14
13.6
11.6
10.3
P/B Ratio
5.99
3.93
3.40
3.01
ROE
20.67
20.67
17.53
14.43
FCFF
2377
5157
2398
3754
FCFF Yield
2.61
5.67
2.64
4.13
Net Debt
-553
-4595
-4244
-7547
BVPS
156.19
238.05
275.3
310.5

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Var%
Dec 24
Dec 23
Var%
Sep 24
Sep 23
Var%
Jun 24
Jun 23
Var%
Net Sales
6,527.90
5,533.80
17.96%
5,269.10
4,505.20
16.96%
5,237.00
4,368.80
19.87%
6,207.50
5,139.60
20.78%
Expenses
4,402.40
3,908.60
12.63%
3,881.50
3,402.80
14.07%
3,821.00
3,304.90
15.62%
4,123.50
3,634.30
13.46%
EBITDA
2,125.50
1,625.20
30.78%
1,387.60
1,102.40
25.87%
1,416.00
1,063.90
33.10%
2,084.00
1,505.30
38.44%
EBIDTM
32.56%
29.37%
26.33%
24.47%
27.04%
24.35%
33.57%
29.29%
Other Income
80.60
161.70
-50.15%
57.50
37.70
52.52%
113.60
136.20
-16.59%
63.20
36.00
75.56%
Interest
76.60
34.60
121.39%
32.00
19.80
61.62%
25.10
8.70
188.51%
32.20
18.10
77.90%
Depreciation
237.90
205.30
15.88%
229.00
194.80
17.56%
233.60
184.20
26.82%
215.30
179.80
19.74%
PBT
1,672.00
1,547.00
8.08%
1,184.10
925.50
27.94%
1,270.90
1,007.20
26.18%
1,899.70
1,329.20
42.92%
Tax
423.20
321.20
31.76%
179.50
213.80
-16.04%
373.10
226.40
64.80%
436.10
216.10
101.80%
PAT
1,248.80
1,225.80
1.88%
1,004.60
711.70
41.15%
897.80
780.80
14.98%
1,463.60
1,113.10
31.49%
PATM
19.13%
22.15%
19.07%
15.80%
17.14%
17.87%
23.58%
21.66%
EPS
11.64
11.75
-0.94%
10.17
7.80
30.38%
9.06
7.91
14.54%
14.11
10.74
31.38%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Net Sales
-
23,241.50
19,547.40
17,237.40
15,109.90
14,403.50
14,253.10
13,165.60
11,954.50
9,376.50
9,426.80
Net Sales Growth
-
18.90%
13.40%
14.08%
4.90%
1.06%
8.26%
10.13%
27.49%
-0.53%
 
Cost Of Goods Sold
-
5,345.40
5,260.10
5,335.70
4,757.00
4,094.20
4,243.30
4,141.30
3,656.90
3,065.00
2,673.20
Gross Profit
-
17,896.10
14,287.30
11,901.70
10,352.90
10,309.30
10,009.80
9,024.30
8,297.60
6,311.50
6,753.60
GP Margin
-
77.00%
73.09%
69.05%
68.52%
71.57%
70.23%
68.54%
69.41%
67.31%
71.64%
Total Expenditure
-
16,348.00
14,248.40
13,665.50
11,935.20
11,018.20
11,472.90
10,187.20
9,125.90
7,475.00
7,097.30
Power & Fuel Cost
-
358.20
366.30
343.50
299.30
231.60
252.90
231.60
211.40
174.50
155.40
% Of Sales
-
1.54%
1.87%
1.99%
1.98%
1.61%
1.77%
1.76%
1.77%
1.86%
1.65%
Employee Cost
-
3,289.70
2,789.00
2,456.40
2,177.70
2,069.50
2,169.80
1,903.20
1,644.70
1,485.20
1,119.00
% Of Sales
-
14.15%
14.27%
14.25%
14.41%
14.37%
15.22%
14.46%
13.76%
15.84%
11.87%
Manufacturing Exp.
-
3,445.60
2,758.10
2,639.80
2,272.30
2,271.40
2,230.00
1,923.20
1,680.40
955.30
1,397.60
% Of Sales
-
14.83%
14.11%
15.31%
15.04%
15.77%
15.65%
14.61%
14.06%
10.19%
14.83%
General & Admin Exp.
-
933.50
625.00
620.30
506.70
444.00
582.60
583.40
398.70
466.00
356.40
% Of Sales
-
4.02%
3.20%
3.60%
3.35%
3.08%
4.09%
4.43%
3.34%
4.97%
3.78%
Selling & Distn. Exp.
-
2,362.20
1,800.10
1,674.60
1,373.30
1,358.60
1,468.40
1,033.30
1,129.40
826.40
979.60
% Of Sales
-
10.16%
9.21%
9.71%
9.09%
9.43%
10.30%
7.85%
9.45%
8.81%
10.39%
Miscellaneous Exp.
-
613.40
649.80
595.20
548.90
548.90
525.90
371.20
404.40
502.60
979.60
% Of Sales
-
2.64%
3.32%
3.45%
3.63%
3.81%
3.69%
2.82%
3.38%
5.36%
4.41%
EBITDA
-
6,893.50
5,299.00
3,571.90
3,174.70
3,385.30
2,780.20
2,978.40
2,828.60
1,901.50
2,329.50
EBITDA Margin
-
29.66%
27.11%
20.72%
21.01%
23.50%
19.51%
22.62%
23.66%
20.28%
24.71%
Other Income
-
459.60
369.40
474.60
390.70
47.40
117.10
208.50
133.00
147.10
116.60
Interest
-
191.00
81.20
129.90
127.00
158.80
341.80
195.80
110.80
63.10
52.80
Depreciation
-
915.80
764.10
722.70
713.00
669.60
696.50
598.60
538.80
373.30
292.10
PBT
-
6,246.30
4,823.10
3,193.90
2,725.40
2,604.30
1,859.00
2,392.50
2,312.00
1,612.20
2,101.20
Tax
-
1,411.90
977.50
587.80
511.70
193.60
319.80
530.30
564.40
128.90
177.40
Tax Rate
-
23.43%
20.33%
22.70%
18.03%
8.07%
21.39%
22.26%
24.41%
8.00%
8.45%
PAT
-
4,467.70
3,718.10
1,870.30
2,195.40
2,154.20
1,147.80
1,801.90
1,713.00
1,453.90
1,890.90
PAT before Minority Interest
-
4,614.80
3,831.40
2,001.90
2,326.40
2,205.60
1,175.60
1,851.80
1,747.60
1,483.00
1,921.30
Minority Interest
-
-147.10
-113.30
-131.60
-131.00
-51.40
-27.80
-49.90
-34.60
-29.10
-30.40
PAT Margin
-
19.22%
19.02%
10.85%
14.53%
14.96%
8.05%
13.69%
14.33%
15.51%
20.06%
PAT Growth
-
20.16%
98.80%
-14.81%
1.91%
87.68%
-36.30%
5.19%
17.82%
-23.11%
 
EPS
-
44.40
36.95
18.59
21.82
21.41
11.41
17.91
17.02
14.45
18.79

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Shareholder's Funds
23,953.10
19,829.50
17,515.80
16,999.60
12,992.30
10,375.70
10,386.30
8,744.50
6,960.00
5,699.20
Share Capital
100.60
100.60
101.20
102.40
102.40
102.40
102.40
102.40
102.40
102.40
Total Reserves
23,852.50
19,728.90
17,414.60
16,897.20
12,889.90
10,273.30
10,283.90
8,642.10
6,857.60
5,596.80
Non-Current Liabilities
-542.10
193.10
-725.00
-193.60
19.40
2,853.90
3,491.10
2,122.20
1,903.30
736.10
Secured Loans
0.00
0.00
0.00
0.00
0.00
1,953.60
2,332.80
200.60
319.60
393.80
Unsecured Loans
0.00
0.00
0.00
362.10
609.50
1,261.00
1,616.90
2,354.50
2,148.80
502.60
Long Term Provisions
383.90
309.70
271.80
325.00
309.50
235.20
184.10
155.90
151.20
120.70
Current Liabilities
9,041.60
5,339.70
5,526.70
7,826.80
7,861.30
8,269.40
7,342.50
6,083.00
5,305.80
3,461.00
Trade Payables
2,305.80
2,126.70
2,125.00
2,137.80
2,205.90
2,044.30
1,922.60
1,888.40
1,547.90
1,308.10
Other Current Liabilities
2,499.20
1,677.60
1,798.50
1,967.50
2,166.20
2,126.30
2,033.60
1,484.90
1,212.10
860.70
Short Term Borrowings
3,169.50
768.60
1,081.00
3,314.10
3,070.90
3,826.50
3,196.90
2,557.50
2,476.90
1,210.90
Short Term Provisions
1,067.10
766.80
522.20
407.40
418.30
272.30
189.40
152.20
68.90
81.30
Total Liabilities
34,857.90
27,634.40
24,490.00
26,687.00
22,810.30
22,833.70
22,512.80
17,140.70
14,325.20
10,032.10
Net Block
13,133.70
12,368.50
11,520.90
12,188.50
12,132.80
12,230.50
12,163.70
6,482.60
5,755.10
3,747.90
Gross Block
21,699.80
19,919.80
18,343.80
17,650.90
17,345.00
16,781.50
15,702.30
9,349.10
8,102.90
5,767.30
Accumulated Depreciation
8,566.10
7,551.30
6,822.90
5,462.40
5,212.20
4,551.00
3,538.60
2,866.50
2,345.80
2,016.80
Non Current Assets
17,811.80
16,135.20
14,477.60
14,438.20
14,094.30
14,118.30
14,014.70
8,911.00
8,302.90
5,751.70
Capital Work in Progress
2,691.90
2,423.30
1,200.70
725.90
783.20
741.50
837.20
1,527.20
1,543.30
950.80
Non Current Investment
1,556.70
968.00
927.30
934.80
631.20
552.20
443.60
470.90
385.70
217.10
Long Term Loans & Adv.
400.10
344.50
358.70
369.30
323.30
332.00
410.40
300.00
384.70
661.20
Other Non Current Assets
29.40
30.90
470.00
219.70
223.80
262.10
159.80
130.30
234.10
174.70
Current Assets
17,046.10
11,419.80
10,008.20
12,095.20
8,716.00
8,715.40
8,498.10
8,229.70
6,022.30
4,280.40
Current Investments
4,851.10
252.50
619.30
2,353.20
198.90
212.80
229.90
274.80
49.10
199.10
Inventories
3,944.00
3,441.90
3,413.30
3,719.40
3,236.20
2,789.00
2,688.00
2,385.30
1,803.70
1,337.10
Sundry Debtors
4,024.70
5,220.20
4,416.80
3,340.30
3,127.30
3,663.20
3,950.80
3,206.30
2,277.50
1,746.60
Cash & Bank
2,956.80
1,105.10
573.10
1,106.90
888.30
964.90
548.90
1,314.90
1,543.50
638.70
Other Current Assets
1,269.50
664.20
274.00
229.90
1,265.30
1,085.50
1,080.50
1,048.40
348.50
358.90
Short Term Loans & Adv.
717.30
735.90
711.70
1,345.50
741.40
643.90
584.50
527.70
268.50
234.80
Net Current Assets
8,004.50
6,080.10
4,481.50
4,268.40
854.70
446.00
1,155.60
2,146.70
716.50
819.40
Total Assets
34,857.90
27,555.00
24,485.80
26,533.40
22,810.30
22,833.70
22,512.80
17,140.70
14,325.20
10,032.10

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Cash From Operating Activity
6,776.70
3,196.30
2,688.80
2,104.50
3,293.90
2,931.50
1,281.90
919.30
1,311.70
1,893.50
PBT
6,026.70
4,838.10
2,582.70
5,232.30
2,284.80
1,495.40
2,382.10
2,312.00
1,611.90
2,098.70
Adjustment
1,020.40
546.70
933.90
-2,117.20
1,163.00
1,474.40
539.10
624.30
333.70
249.80
Changes in Working Capital
1,531.50
-902.70
-235.80
-336.00
191.10
263.80
-971.70
-1,383.90
-411.20
271.70
Cash after chg. in Working capital
8,578.60
4,482.10
3,280.80
2,779.10
3,638.90
3,233.60
1,949.50
1,552.40
1,534.40
2,620.20
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-1,801.90
-1,285.80
-592.00
-674.60
-345.00
-302.50
-675.40
-602.30
-237.60
-646.00
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.40
7.80
-30.80
14.90
-80.70
Cash From Investing Activity
-8,372.30
-1,475.20
1,535.00
-1,000.30
-724.60
-1,012.30
-4,238.70
-973.70
-2,871.90
-863.50
Net Fixed Assets
-776.80
-572.20
-669.30
-490.20
-462.80
-289.60
-1,652.30
-600.20
-557.40
-531.50
Net Investments
-4,208.50
-2,403.70
238.70
1,352.60
-66.50
-2,208.90
-577.10
305.60
-1,606.20
-108.40
Others
-3,387.00
1,500.70
1,965.60
-1,862.70
-195.30
1,486.20
-2,009.30
-679.10
-708.30
-223.60
Cash from Financing Activity
2,014.20
-1,778.80
-4,400.40
-868.30
-2,547.70
-1,528.20
1,884.60
51.50
2,315.80
-934.80
Net Cash Inflow / Outflow
418.60
-57.70
-176.60
235.90
21.60
391.00
-1,072.20
-2.90
755.60
95.20
Opening Cash & Equivalents
413.00
487.80
657.80
888.30
1,177.70
778.80
1,589.70
1,592.60
837.00
737.90
Closing Cash & Equivalent
826.80
413.00
487.80
1,106.90
1,087.20
1,177.70
778.80
1,589.70
1,592.60
837.00

Financial Ratios

Consolidated /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Book Value (Rs.)
238.10
197.11
173.08
166.01
126.88
101.33
101.43
85.40
67.97
55.66
ROA
14.77%
14.70%
7.82%
9.40%
9.66%
5.18%
9.34%
11.11%
12.18%
20.14%
ROE
21.08%
20.52%
11.60%
15.51%
18.88%
11.32%
19.36%
22.26%
23.43%
38.62%
ROCE
26.06%
24.90%
13.64%
15.30%
14.23%
10.02%
15.89%
18.41%
16.50%
28.60%
Fixed Asset Turnover
2.20
1.98
1.88
1.69
1.69
0.88
1.05
1.38
1.38
1.76
Receivable days
36.93
46.37
41.75
39.94
42.92
97.49
99.21
83.37
76.72
63.29
Inventory Days
29.51
32.98
38.39
42.95
38.08
70.13
70.33
63.69
59.88
54.52
Payable days
151.33
147.51
145.80
166.64
189.45
64.85
68.81
68.11
74.18
65.30
Cash Conversion Cycle
-84.89
-68.16
-65.67
-83.76
-108.45
102.77
100.73
78.94
62.42
52.51
Total Debt/Equity
0.13
0.04
0.07
0.25
0.35
0.77
0.76
0.62
0.75
0.43
Interest Cover
32.55
60.22
20.94
23.35
16.11
5.38
13.17
21.87
26.55
40.75

Annual Reports:

FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016

News Update:


  • Zydus Lifesciences gets NoC for ZDS-Varenicline Tablets 0.5 &1 mg
    7th Aug 2025, 17:53 PM

    This is the group’s first NOC approval in Canada

    Read More
  • Zydus Lifesciences’ arm completes acquisition of 85.6% equity shares of Amplitude Surgical SA
    30th Jul 2025, 10:30 AM

    Zydus MedTech France now holds 85.6% of the share capital and voting rights of the Target Entity

    Read More
  • Zydus Lifesciences gets USFDA’s tentative approval for Ibrutinib tablets
    24th Jul 2025, 16:15 PM

    The group now has 420 approvals and has so far filed around 484 ANDAs since the commencement of the filing process in FY 2003-04

    Read More
  • USFDA concludes RRA at Zydus Lifesciences’ Gujarat formulations manufacturing facility
    17th Jul 2025, 10:11 AM

    At the closure, there were no observations noted, and the site was recommended for approval

    Read More
  • Zydus Lifesciences gets final nod for Celecoxib Capsules from USFDA
    16th Jul 2025, 10:11 AM

    The group now has 428 approvals and has so far filed 492 ANDAs since the commencement of the filing process in FY 2003-04

    Read More
  • Zydus Lifesciences’ arm incorporates wholly owned subsidiary in USA
    14th Jul 2025, 11:30 AM

    The immediate objective of incorporation of Zylidac is to acquire the target assets of Agenus

    Read More
  • USFDA concludes GMP follow-up inspection at Zydus Lifesciences’ Ahmedabad site
    19th Jun 2025, 10:08 AM

    The inspection is closed with 2 observations and none of them were related to data integrity

    Read More
  • Zydus Lifesciences gets EIR for Ankleshwar API manufacturing facility from USFDA
    12th Jun 2025, 10:12 AM

    This facility underwent an inspection from March 10, 2025 to March 14, 2025

    Read More
  • Zydus Lifesciences gets EIR for Vadodara API manufacturing facility from USFDA
    10th Jun 2025, 16:14 PM

    This facility underwent an inspection from April 21 to April 25 2025

    Read More
  • Zydus Lifesciences’ arm enters into SPA with Agenus Inc
    4th Jun 2025, 09:30 AM

    The acquisition is expected to be completed within 60 days from the date of execution of the definitive agreement, with a potential 30- days extension

    Read More
  • Zydus Lifesciences gets USFDA’s tentative approval for Rifaximin Tablets
    2nd Jun 2025, 09:38 AM

    The group now has 427 approvals and has so far filed 492 ANDAs since the commencement of the filing process in FY 2003-04

    Read More
  • Zydus Lifesciences to subscribe equity shares of Torrent Urja 26, Torrent Urja 25
    29th May 2025, 11:40 AM

    The Company has entered into SSSA to acquire up to 26.20% equity shares of Torrent Urja 26, for setting up captive hybrid power project in Gujarat.

    Read More
  • Zydus Lifesciences’ NCE Usnoflast receives Fast Track Designation from USFDA
    28th May 2025, 12:50 PM

    Usnoflast is a novel oral NLRP3 inhibitor for the treatment of amyotrophic lateral sclerosis

    Read More
  • Zydus Lifesciences gets USFDA’s final nod for Isotretinoin capsules
    26th May 2025, 10:12 AM

    The group now has 427 approvals and has so far filed 492 ANDAs since the commencement of the filing process in FY 2003-04

    Read More
  • Zydus Lifesciences receives EIR from USFDA for Ambernath facility
    14th May 2025, 15:13 PM

    The EIR report has classified it as No Action Indicated

    Read More
  • Zydus Lifesciences gets USFDA’s approval for Glatiramer Acetate Injection
    9th May 2025, 09:17 AM

    Zydus’ generic Glatiramer Acetate Injection, developed in collaboration with Chemi S.p.A., will be manufactured entirely in Europe

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.